Klaria accelerates its business development efforts
With Klaria’s Sumatriptan Alginate Film product in approval process Klaria is now accelerating its business development efforts and has engaged Ernst & Young AB Corporate Finance (EY) to identify potential strategic partnerships for its assets. In line with this, several options are being considered that could lead to different potential outcomes, with the objective to maximize shareholder value.Klaria will cooperate with EY to identify and establish contacts with potential strategic partners. The primary focus will be to secure a partner for the sumatriptan product in both the EU and US –